Abstract 1403P
Background
Several phase II/III studies have shown that neoadjuvant immunotherapy have promising efficacy in patients with resectable esophageal squamous cell carcinoma (ESCC). In our previous reported TD-NICE study, 36 of 45 patients who received neoadjuvant tislelizumab combined with chemotherapy and surgery, major pathological response (MPR) and pathological complete response (pCR) is 72.0% and 50.0%. Here, we report update long-term follow-up data.
Methods
Treatment-naïve patients with resectable ESCC were enrolled. Patients received 3 cycles (3 weeks/cycle) tislelizumab (200 mg, D1), carboplatin (AUC=5, D1), and albumin-bound paclitaxel (130 mg/m2 on D1,8). The primary endpoint was MPR, secondary endpoint included pCR, R0 rate, tumor downstaging rate and safety.
Results
By April 2024, with a median follow-up of 39.2 months, 17 patients (37.8%) had died (11 in the surgery group and 6 in the non- surgery group). The median OS of the ITT group and the surgery group was not reached, and the median OS of the non- surgery group was 32.9m. The 1-year, 2-year and 3-year OS rates were 86.7%, 71.1% and 64.3% in all patients, 88.9%, 77.8%, 69.3% and 66.7%, 55.6%, 44.4% in the surgery and non- surgery groups, respectively. The OS results of R0 resection, pCR and MPR subgroups are shown in the table below. The mOS of R1 & R2 group was 20.5 months, which was statistically lower compared with R0 group (p=0.034), while there was no statistically significant difference among other subgroups. The EFS at 1 year, 2 years and 3 years were 88.9%, 75.0% and 69.3%. The trends of EFS were similar as OS.
Table: 1403P
Subgroup | 1y-OS, % | 2y-OS, % | 3y-OS, % |
ITT | 86.7 | 71.1 | 64.3 |
Surgery | 91.7 | 77.8 | 69.3 |
Non-surgery | 66.7 | 55.6 | 44.4 |
R0 | 96.6 | 82.8 | 75.7 |
R1&R2 | 71.4 | 42.9 | 42.9 |
MPR | 96.2 | 80.8 | 72.9 |
Non-MPR | 80.0 | 60.0 | 60.0 |
pCR | 94.4 | 77.8 | 72.2 |
Non-pCR | 88.9 | 72.2 | 66.7 |
Conclusions
Neoadjuvant tislelizumab combined with chemotherapy showed long-term survival benefit in ESCC patients, especially in R0 resection and surgery patients.
Clinical trial identification
ChiCTR2000037488.
Editorial acknowledgement
Legal entity responsible for the study
The Second Affiliated Hospital of Air Force Medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
951P - CA19-9-related macrophage polarization has prognostic value in patients with HCC after immune checkpoint inhibitor treatment
Presenter: Meiyan Zhu
Session: Poster session 17
952P - Comprehensive analysis of cytokines and PDL1 before and after administration of atezolizumab and bevasizumab in patients with HCC
Presenter: Kyoji Ito
Session: Poster session 17
953P - Vessels that encapsulate tumor clusters (VETC): A promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations
Presenter: Yanjiang Yin
Session: Poster session 17
954P - Evaluation of antigen-specific CD8 T cell responses to predict efficacy of atezolizumab and bevacizumab treatment in hepatocellular carcinoma
Presenter: Angélique Vienot
Session: Poster session 17
957P - Modelling immune-mediated cytotoxicity for HCC with patient-derived organoid co-culture platform
Presenter: Tsz Tung Kwong
Session: Poster session 17
958P - Utilizing personalized tumor-specific methylation haplotypes of circulating tumor DNA for monitoring minimal residual disease in hepatocellular carcinoma patients after curative resection
Presenter: Xinrong Yang
Session: Poster session 17
959P - Machine learning-based MRI radiomics predicts overall survival of unresectable hepatocellular carcinoma undergoing transarterial chemoembolization plus PD-(L)1 inhibitors and molecular targeted therapy
Presenter: Bin-Yan Zhong
Session: Poster session 17
960P - Development and validation of a novel digital PCR assay targeting circulating tumor DNA methylation biomarkers for hepatocellular carcinoma screening
Presenter: Hee-Jung Wang
Session: Poster session 17